137 related articles for article (PubMed ID: 8064508)
1. [Immunotherapy of malignant lymphoma with interleukin-2 and sizofiran--a basic study on EL-4 lymphoma-transplanted mice].
Hashimoto J
Nihon Jibiinkoka Gakkai Kaiho; 1994 Jul; 97(7):1235-49. PubMed ID: 8064508
[TBL] [Abstract][Full Text] [Related]
2. Augmentation of antitumor effect by combined administration with interleukin-2 and sizofiran, a single glucan, on murine EL-4 lymphoma.
Kano Y; Kakuta H; Hashimoto J
Biotherapy; 1996; 9(4):241-7. PubMed ID: 9012543
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of metastasis by combined administration with interleukin-2 and sizofiran, a single glucan--immunohistochemical study.
Kano Y; Kakuta H; Hashimoto J
Biotherapy; 1996; 9(4):263-9. PubMed ID: 9012546
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of the antitumor effect of adoptive immunotherapy by in vivo sensitization of EL-4 lymphoma and pre-treatment with sizofiran.
Kano Y; Kakuta H; Hashimoto J
Biotherapy; 1998; 11(1):1-6. PubMed ID: 9617459
[TBL] [Abstract][Full Text] [Related]
5. Augmentation of anti-tumor effect of interleukin 2 with sizofiran in mice.
Ikeuchi K
Keio J Med; 1991 Sep; 40(3):132-8. PubMed ID: 1753556
[TBL] [Abstract][Full Text] [Related]
6. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
[TBL] [Abstract][Full Text] [Related]
7. [Combined effect of intraperitoneally administered OK-432 and recombinant interleukin (rIL-2) against mouse tumors].
Fujioka T; Shiraishi M; Tanji S; Koike H; Kumagai K; Kubo T; Ohhori T
Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):948-56. PubMed ID: 2789265
[TBL] [Abstract][Full Text] [Related]
8. Combined effects of intraperitoneal administration of recombinant interleukin-2 and streptococcal preparation OK-432 in murine tumors.
Fujioka T; Ishikura K; Tanji S; Okamoto T; Koike H; Aoki H; Ohhori T; Kubo T
Int J Immunopharmacol; 1990; 12(4):419-26. PubMed ID: 2391188
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
Hinuma S; Naruo K; Shiho O; Tsukamoto K
Immunology; 1986 Oct; 59(2):251-9. PubMed ID: 3490435
[TBL] [Abstract][Full Text] [Related]
10. Cytokine-mediated immunotherapy following autologous bone marrow transplantation in lymphoma and evidence of interleukin-2-induced immunomodulation in allogeneic transplants.
Slavin S; Nagler A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S59-67. PubMed ID: 9457396
[TBL] [Abstract][Full Text] [Related]
11. Schizophyllan (SPG)-treated macrophages and anti-tumor activities against syngeneic and allogeneic tumor cells. I. Characteristics of SPG-treated macrophages.
Sugawara I; Lee KC; Wong M
Cancer Immunol Immunother; 1984; 16(3):137-44. PubMed ID: 6322974
[TBL] [Abstract][Full Text] [Related]
12. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
13. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
14. Effects of cyclosporin on C57BL/6 splenocytes before and after culture with high-dose recombinant interleukin-2: implications for immunosuppression with cyclosporin.
Sutherland F; Borkenhagen K; Temple L; Bryant LD; Lafreniere R
Cancer Immunol Immunother; 1990; 31(5):312-20. PubMed ID: 2376049
[TBL] [Abstract][Full Text] [Related]
15. Changes in lymphocyte subsets following multiple administration of recombinant interleukin-2 plus recombinant interferon-beta or -gamma in tumor-bearing mice.
Iigo M; Nishikata K; Nakajima Y; Moriyama M
Jpn J Cancer Res; 1989 Jun; 80(6):554-61. PubMed ID: 2527216
[TBL] [Abstract][Full Text] [Related]
16. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
17. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.
Phillips JH; Gemlo BT; Myers WW; Rayner AA; Lanier LL
J Clin Oncol; 1987 Dec; 5(12):1933-41. PubMed ID: 3500280
[TBL] [Abstract][Full Text] [Related]
18. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
[TBL] [Abstract][Full Text] [Related]
19. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract][Full Text] [Related]
20. Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.
Mochizuki S; Morishita H; Kobiyama K; Aoshi T; Ishii KJ; Sakurai K
J Control Release; 2015 Dec; 220(Pt A):495-502. PubMed ID: 26562685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
